Rigel Pharmaceuticals (RIGL) Return on Capital Employed (2011 - 2026)

Rigel Pharmaceuticals' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 29.69% for Q1 2026.

• In Q1 2026, Return on Capital Employed fell 1282.0% year-over-year to 29.69%; the TTM figure through Mar 2026 stood at 29.69% (down 1282.0% YoY), while the FY2025 annual figure was 52.38%, up 2108.0% from the prior year.
• Return on Capital Employed was 29.69% for Q1 2026 at Rigel Pharmaceuticals, down from 45.0% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 99.87% in Q2 2025 to a low of 106.05% in Q3 2022.
• Historically, Return on Capital Employed has averaged 13.54% across 5 years, with a median of 30.0% in 2023.
• The sharpest annual moves came in 2022 and 2025: Return on Capital Employed slumped 9870 bps in 2022, then jumped 11298 bps in 2025.
• A 5-year view of Return on Capital Employed shows it stood at 93.0% in 2022, then jumped by 65 bps to 32.52% in 2023, then jumped by 184 bps to 27.37% in 2024, then soared by 64 bps to 45.0% in 2025, then slumped by 34 bps to 29.69% in 2026.
• The last three Return on Capital Employed figures came in at 29.69% (Q1 2026), 45.0% (Q4 2025), and 91.34% (Q3 2025), per Business Quant data.